PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.68%
Revenue growth near Medical - Pharmaceuticals median of 4.56%. Charlie Munger might attribute this to overall industry trends.
7.34%
Gross profit growth 1.25-1.5x Medical - Pharmaceuticals median of 5.94%. Mohnish Pabrai would see if economies of scale justify the premium growth.
14.18%
EBIT growth of 14.18% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
14.18%
Operating income growth of 14.18% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
28.60%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
28.61%
Positive EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong advantage in per-share earnings compared to peers.
28.61%
Positive diluted EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a real advantage in how this firm manages share count or drives net income.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
28.80%
10Y revenue/share CAGR 50-75% of Medical - Pharmaceuticals median of 38.65%. Guy Spier would worry about subpar top-line expansion over the long run.
48.70%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 29.74%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
22.33%
3Y revenue/share growth near Medical - Pharmaceuticals median of 24.78%. Charlie Munger would note typical industry expansions over the short term.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.58%
Net income/share CAGR of 63.58% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
18.88%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 12.15%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
12.08%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 3.63%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
161.83%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 74.13% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
104.73%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 38.24%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
50.85%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 14.77%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
81.82%
Dividend/share CAGR of 81.82% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
77.78%
5Y dividend/share CAGR of 77.78% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
45.45%
3Y dividend/share CAGR of 45.45% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
43.48%
AR growth of 43.48% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
3.24%
Inventory growth of 3.24% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
5.71%
Asset growth of 5.71% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
3.66%
BV/share growth of 3.66% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
111.10%
Debt growth of 111.10% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-40.01%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.